Innovation for the World, Exploring for the Future
SHENZHEN, China, July 1, 2024 /PRNewswire/ -- Recently, the
"Innovation for the World, Exploring for the Future" 2024
International Pharmaceutical Cooperation High-End Forum Kexing
Biopharm's Series of Globalization Activities (China), organized by Kexing Biopharm, was
successfully concluded in Shanghai. Numerous industry experts, senior
figures from the domestic pharmaceutical and investment sectors, as
well as senior executives of pharmaceutical companies from around
20 countries and regions, such as Brazil, Russia, Singapore, South
Korea, Malaysia,
Saudi Arabia, and Africa, who closely collaborated with Kexing
Biopharm attended this forum on sharing and effective
discussions on the current status and development trends in
the global medical market.
During the forum, Kexing Biopharm warmly welcomed and sincerely
thanked the attendees from various backgrounds who had traveled
from afar. In addition, they provided a comprehensive introduction
to the Company's internationalization strategy and plans for the
future. Kexing Biopharm emphasized its commitment to leveraging its
overseas commercial platform to deliver high-quality products and
comprehensive medication solutions for global patients. It
specifically mentioned the successful acquisition of the EU GMP
certificate for its first introduced product, albumin-bound
paclitaxel, indicating a significant step forward in its global
expansion. With a strong focus on international commercialization
this year and leveraging years of international experience, the
Company aims to become the best partner for high-quality Chinese
pharmaceuticals worldwide.
Meanwhile, representatives from partner companies in
Brazil, Malaysia, Saudi
Arabia, and Africa,
respectively shared insights into the local pharmaceutical
development status, distribution channels, medication requirements,
market access, and collaborative opportunities, providing
clarification and showcasing the power of international win-win
cooperation among the guests present at the event. Additionally,
onsite strategic cooperation agreements were signed between Kexing
Biopharm and various overseas partners, showcasing a reaffirmed
commitment to continued collaboration and shared vision for the
development of the pharmaceutical industry.
Simultaneously, during the CPHI exhibition from June 19th to 21, Kexing Biopharm presented a
diverse portfolio of over twenty high-quality drugs covering the
oncology pipeline, immunotherapy pipeline, metabolic disease
pipeline, and nephropathy pipeline, including monoclonal
antibodies, peptides, and small molecules.
News of victory keeps pouring in, on June
25, Kexing Biopharm (688136.SH) made it to the "2023 China
Biopharmaceutical (Blood Product, Vaccine, and Insulin) Enterprise
Top 20 List" in the "2023 China Pharmaceutical Industry Top 100
List Series," which was the third time in a row.
View original
content:https://www.prnewswire.co.uk/news-releases/2024-international-pharmaceutical-cooperation-high-end-forum-kexing-biopharms-series-of-globalization-activities-china-successfully-concluded-302186883.html